Who Owns Renovaro Biosciences Company?

Renovaro Biosciences Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Renovaro Biosciences?

Unraveling the ownership structure of a company is like deciphering its DNA, revealing its strategic blueprint and future potential. Renovaro Biosciences, formerly Enochian Biosciences, underwent a significant transformation, including a name change and strategic acquisitions. This evolution, particularly the integration of AI in its cancer diagnostics, makes understanding Renovaro Biosciences SWOT Analysis crucial for any investor.

This exploration into "Who owns Renovaro" will examine the influence of Renovaro investors, the role of Renovaro management, and the impact of its evolving ownership on its strategic direction. Understanding the company's ownership is essential for assessing its long-term viability and potential for growth, especially given the company's focus on oncology and AI integration. Key questions to be answered include: Who is the CEO of Renovaro Biosciences and who are the major shareholders of Renovaro?

The story of Renovaro Biosciences' ownership begins in 2011, marked by a series of name changes before settling on its current identity. The company's early years were shaped by its founders and the initial distribution of equity, which would later be complicated by significant controversies. Understanding the company's ownership structure is crucial for investors and those interested in the Competitors Landscape of Renovaro Biosciences.

Serhat Gümrükcü, a co-founder, played a pivotal role as the inventor of the company's core drug platform. His subsequent sale of the platform research in January 2018 for $21 million to a new venture, Enochian Biosciences, marked a significant transaction in the company's early financial history. The appointment of Rene Sindlev as board chair around the same time further shaped the leadership.

Mark Dybul, who later became CEO, received shares in August 2017, when the company was still operating privately under the Enochian name. The company then went public in early 2018 through a merger with an OTC-listed company, which provided an avenue for public investment and further changes in ownership structure. The company's early ownership was complex, with various individuals and entities holding shares.

Early Founders

Serhat Gümrükcü, a co-founder, was the inventor of the main drug platform. His sale of the drug platform research to a new venture significantly impacted the company's financial trajectory. The initial equity split among all founders is not readily available in the search results.

Leadership Changes

Rene Sindlev became the board chair around the time of Gümrükcü's platform sale. Mark Dybul, who later became CEO, was awarded shares in August 2017. These leadership changes reflect the company's evolving management structure.

Going Public

The company went public in early 2018 through a merger with an OTC-listed company. This move allowed for public investment and changed the company's ownership dynamics. This transition was a critical step in its financial evolution.

Key Shareholders

As of late February 2024, Serhat Gümrükcü remained the largest single shareholder. This highlights the enduring influence of early stakeholders. This ownership structure is crucial for understanding the company's governance.

Controversies and Impact

Controversies surrounding Serhat Gümrükcü, including allegations of falsified study data and murder-for-hire charges, have significantly impacted the company. These legal issues have influenced the company's reputation. These events have undoubtedly shaped the company's early ownership narrative.

Ownership Dynamics

The early ownership narrative is complex, with key individuals and entities holding shares. The company's ownership structure has evolved over time. This evolution is essential for investors to understand.

Key Takeaways on Renovaro Ownership

Understanding the early ownership of Renovaro Biosciences provides insights into its history and current structure. The company's transformation from its founding to its current form involved significant changes in leadership and ownership.

• The company's early ownership was significantly influenced by Serhat Gümrükcü.
• Rene Sindlev and Mark Dybul played key roles in the company's leadership.
• The merger with an OTC-listed company in early 2018 marked a pivotal moment.
• Controversies surrounding a co-founder have shaped the company's narrative.
• As of late February 2024, Gümrükcü remained the largest single shareholder.

Renovaro Biosciences SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Renovaro Inc. (formerly Renovaro Biosciences Inc.) has evolved significantly since its public listing in early 2018. As of June 10, 2025, the company's market capitalization stood at approximately $65.5 million, with around 172 million shares outstanding. This structure reflects a mix of institutional, retail, and individual investors, with institutional investors holding a notable portion of the shares.

A key event impacting the ownership structure was the acquisition of GEDi Cube Intl Ltd. in February 2024. This acquisition, a stock-for-stock deal, resulted in the sellers of GEDi Cube holding approximately 49% of Renovaro's outstanding common stock immediately after the closing. This strategic move shifted the company's focus towards GEDi Cube's technologies, particularly in AI-driven cancer diagnostics. The company's history and strategic shifts can be further understood by reading about the Growth Strategy of Renovaro Biosciences.

Major institutional investors have shown active interest in Renovaro stock. In Q4 2024, BlackRock, Inc. increased its holdings significantly. As of March 30, 2025, BlackRock Inc. held 4.53% of the shares, Vanguard Group Inc. held 3.49%, and Geode Capital Management, LLC held 1.46%. Insider ownership, as reported by TipRanks, is approximately 41.95%. Top insider shareholders include Karen Brink, William Anderson Wittekind, Rene Sindlev, and Ole Abildgaard.

Key Takeaways on Renovaro Ownership

The ownership of Renovaro Biosciences is diverse, with significant holdings by institutional investors and a substantial portion held by public companies and individual investors.

• Institutional investors such as BlackRock, Inc. and Vanguard Group Inc. hold notable positions.
• The acquisition of GEDi Cube in 2024 was a pivotal event, changing the company's strategic direction.
• Insider ownership is concentrated among key individuals.
• The company's stock symbol is RENB.

Renovaro Biosciences PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of Renovaro Biosciences plays a critical role in guiding the company. As of February 9, 2024, the board consisted of ten members, reflecting the company's governance structure and ownership dynamics. The board includes key executives and independent directors who oversee the company's operations and strategic direction. The composition of the board is crucial for making decisions and ensuring the company's long-term success.

Key figures on the board include David H. Weinstein as CEO and Director, and Nathen Fuentes as Chief Financial Officer. Independent directors like Maurice Van Tilburg (Independent Chairman), Douglas W. Calder, Mark Anthony Collins, and James A. McNulty also play essential roles. The presence of independent directors, particularly those meeting Nasdaq listing rules, is important for maintaining corporate governance standards.

As of December 29, 2023, Renovaro had 67,224,089 shares of Common Stock outstanding, each with one vote. Additionally, there were 561,010 shares of Series A Convertible Preferred Stock, each entitled to ten votes. This dual-class structure gives holders of Series A Preferred Stock significant control. These details are essential for understanding the distribution of power within the company and the potential influence of different shareholder groups. For more information, you can read Brief History of Renovaro Biosciences.

Understanding Renovaro's Board and Voting Power

The Board of Directors at Renovaro Biosciences is pivotal for the company's governance and strategic direction. The voting structure, with its dual-class shares, significantly impacts shareholder power. Understanding these elements is crucial for anyone interested in Renovaro ownership and Renovaro stock.

• The Board expanded to ten members as of February 2024.
• Dual-class shares give Series A Preferred Stock holders outsized voting control.
• Legal actions, like the October 2023 lawsuits, can influence decision-making.
• Key executives and independent directors shape the company's direction.

Renovaro Biosciences Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the last few years, Renovaro Biosciences has undergone substantial shifts, notably changing its name from Enochian Biosciences Inc. in August 2023 and then to Renovaro Inc. in February 2024. These changes coincided with strategic acquisitions and ownership adjustments. The acquisition of GEDi Cube Intl Ltd., completed in February 2024, saw GEDi Cube's sellers holding approximately 49% of Renovaro's common stock post-closing. This move significantly redirected the company's focus toward AI-driven cancer diagnostics.

Further acquisitions, such as BioSymetrics in February 2025 and a planned acquisition of Predictive Oncology, Inc. in March 2025, indicate Renovaro's commitment to integrating AI in healthcare. In September 2024, RenovaroCube announced a strategic offering of up to 20% ownership. These moves reflect Renovaro's evolving business strategy and its efforts to secure funding and manage financial obligations, especially given the company's current lack of sales revenue, which is expected to continue until product approvals.

Ownership trends show increased institutional activity. In Q4 2024, 43 institutional investors increased their positions in Renovaro stock, while 15 decreased theirs. Notable increases included BlackRock, Inc. (+79.9%), GEODE CAPITAL MANAGEMENT, LLC (+48.4%), STATE STREET CORP (+56.0%), and UBS GROUP AG (+1543.9%). As of May 2025, institutional investors held 13.49% of shares, and mutual funds held 13.43%. Insider holdings remained at 0.54% in May 2025. For more information about the company, you can read this article about Renovaro Biosciences.

Major Shareholders

Institutional investors, mutual funds, and insiders hold significant portions of Renovaro. In May 2025, institutions held 13.49% of shares, and mutual funds held 13.43%, while insider holdings were at 0.54%.

Recent Financial Activities

In June 2024, Renovaro closed a private placement, raising over $5.8 million. The company has also issued convertible promissory notes and settled debts through stock and warrants, reflecting efforts to manage finances.

Strategic Acquisitions

Renovaro acquired GEDi Cube Intl Ltd. in February 2024, shifting its focus to AI in cancer diagnostics. The company also acquired BioSymetrics and plans to acquire Predictive Oncology, Inc.

Ownership Changes

The acquisition of GEDi Cube led to the sellers holding approximately 49% of Renovaro's common stock. Institutional investor activity increased in Q4 2024, with several firms increasing their positions.

Renovaro Biosciences Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs